

Eligibility criteria  
Unresectable hepatocellular carcinoma  
WHO performance status 0, 1, 2  
Written informed consent



Registration



Treatment  
Sandostatin LAR® 20 mg injection monthly



Follow-up  
Monthly follow-up until patient refusal, unacceptable toxicity,  
investigator discretion or death